John Overdeck’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-48,092
| Closed | -$1.61M | – | 5395 |
|
|
2026
Q1 | $1.61M | Buy |
+48,092
| New | +$1.89M | ﹤0.01% | 2925 |
|
|
2022
Q3 | – | Sell |
-9,970
| Closed | -$28K | – | 2791 |
|
|
2022
Q2 | $28K | Sell |
9,970
-3,933
| -28% | -$10.9K | ﹤0.01% | 2383 |
|
|
2022
Q1 | $47K | Sell |
13,903
-6,733
| -33% | -$34.9K | ﹤0.01% | 2494 |
|
|
2021
Q4 | $127K | Sell |
20,636
-3,754
| -15% | -$39.4K | ﹤0.01% | 4019 |
|
|
2021
Q3 | $338K | Buy |
24,390
+9,840
| +68% | +$137K | ﹤0.01% | 3571 |
|
|
2021
Q2 | $249K | Sell |
14,550
-9,552
| -40% | -$161K | ﹤0.01% | 3639 |
|
|
2021
Q1 | $456K | Sell |
24,102
-9,739
| -29% | -$314K | ﹤0.01% | 3008 |
|
|
2020
Q4 | $980K | Sell |
33,841
-5,666
| -14% | -$164K | ﹤0.01% | 2031 |
|
|
2020
Q3 | $1.49M | Buy |
39,507
+36,282
| +1,125% | +$1.06M | 0.01% | 1490 |
|
|
2020
Q2 | $107K | Buy |
+3,225
| New | +$140K | ﹤0.01% | 2780 |
|
John Overdeck's SLNO Position: Q2 2026 in Review
John Overdeck sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 48,092 shares — an estimated $1.61M sold.
John Overdeck first reported a position in SLNO in Q2 2020 and held it in 10 quarters. The position peaked at $1.61M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- John Overdeck reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- John Overdeck sold 48,092 Soleno Therapeutics shares in Q2 2026, an estimated $1.61M.
- John Overdeck first reported a position in Soleno Therapeutics in Q2 2020 and held it in 10 quarters.
- John Overdeck's Soleno Therapeutics position peaked at $1.61M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.